Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_3
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

recruiting150%
withdrawn150%

Recent Activity

1 active trials
Showing 2 of 2
withdrawnphase_1

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

NCT06732258
recruitingphase_3

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583

Clinical Trials (2)

Showing 2 of 2 trials
NCT06732258Phase 1

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Withdrawn
NCT06095583Phase 3

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2